Business Context and Reporting Period
Company: Minerva Neurosciences, Inc. (Ticker: NERV)
Filing Type: Form 8-K (Current Report)
Date of Report: March 11, 2026
Reporting Period: Quarter and year ended December 31, 2025
This filing serves as a notification that the Company issued a press release regarding its financial results for the period ended December 31, 2025. The detailed financial data is contained in Exhibit 99.1 (the press release), which is furnished but not deemed "filed" for purposes of Section 18 of the Exchange Act.
Key Financial Metrics
The provided text is a cover sheet and does not contain specific numerical data. The following metrics are referenced as being available in the attached press release (Exhibit 99.1) but are not present in this document:
- Revenue
- Profit/Loss
- Cash Flow
- Margins
- Debt and Liquidity
Note: The filing text does not provide a clear value for any specific financial metric.
Material Changes
No material changes or comparative data versus prior periods are disclosed in the text of this Form 8-K. Such information is expected to be detailed in the referenced press release (Exhibit 99.1).
Guidance, Outlook, and Risks
Management Commentary: The filing confirms the issuance of a press release on March 11, 2026, but does not include the content of management's commentary, guidance, or outlook.
Risks and Contingencies: No specific risks or contingencies are described in this document. The filing includes a standard disclaimer that the information in Item 2.02 and Exhibit 99.1 is not incorporated by reference into other filings except as expressly set forth.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for actual revenue, net loss, and cash position figures for Q4 and FY 2025.
- Verify the Company's cash runway and burn rate as disclosed in the press release.
- Check for any updates on clinical trial progress or regulatory milestones mentioned in the press release.
- Confirm if the press release contains updated financial guidance for 2026.